Noema Pharma raises $112M in Series B financing for nervous system disorders 16-Mar-2023 By Liza Laws Oversubscribed, series B financing for Noema Pharma’s clinical stage assets has been successfully closed raising $112 million from new and existing investors.
Cerevance secures $51M in funds to advance drugs for Parkinson's and other CNS diseases 14-Feb-2023 By Liza Laws Series B financing of $51 million (€47 million) has closed a funding round for a Parkinson’s Disease drug advancing to a phase 2 clinical study.